CORE I: Molecular Immunology The core program in immunology was originally designed to function as an intellectual and technical resource for investigators wishing to study immunologic aspects of AIDS-related issues. This required the recruitment of scientists and development of central wet laboratory and flow cytometry facilities capable both of handling virus-infected material and providing the unique resources and reagents necessary for AIDS-related research. These goals have been accomplished by constructing a centralized CFAR immunology laboratory equipped for cellular and molecular studies adjacent to the CFAR BL-3 laboratory, equipping a flow cytometry laboratory with a closed flow system, and identifying a group of core investigators committed to establishing an AIDS immunology program. The centralized CFAR laboratory has been at the forefront of the development of methods and reagents for the analysis of cellular immunity to HIV and SIV. The reagents generated by core staff such as purified viral proteins, recombinant vaccinia virus and retrovirus shuttle vectors, phenotyped target cells, and monoclonal antibodies, are available to center scientists for individual use or collaborative studies. The AIDS flow cytometry facility, which is the only facility at our institution that can handle viable HIV-infected cells, is widely used for AIDS-related studies by investigators from many disciplines. The major projects supported by the core include studies of: (a) immunopathogenesis of HIV disease, both in newly-infected humans and in primate models; (b) vaccine development in humans and primate models; (c) mucosal immunity; (d) specific T cell therapy of HIV with genetically- modified T clones; and (e) immunobiology and therapy of opportunistic infections developing in HIV-infected hosts. The immunology core proposes to continue to provide: (a) technical assistance, training, and reagents necessary for the analysis of immune responses to HIV and SIV; and (b) technical assistance, reagents and the equipment necessary for sophisticated flow cytometric analysis and isolation of virus-infected and uninfected cells. In response to the needs of investigators involved in these projects, the Immunology core proposes to expand its efforts to include: (a) a peptide synthesis facility for production and mapping of T cell and antibody epitopes in HIV/SIV; placement of an upgraded cell analyzer/sorter inside a dedicated BL-3 laboratory; and (c) a humoral immunity facility capable of quantifying antibody responses and neutralizing activity in specimens from primates.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-13
Application #
6299614
Study Section
Project Start
2000-03-01
Project End
2001-02-28
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
13
Fiscal Year
2000
Total Cost
$356,896
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Thomson, Kerry A; Dhanireddy, Shireesha; Andrasik, Michele et al. (2018) Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care 30:121-129
Lohman-Payne, Barbara; Gabriel, Benjamin; Park, Sangshin et al. (2018) HIV-exposed uninfected infants: elevated cord blood Interleukin 8 (IL-8) is significantly associated with maternal HIV infection and systemic IL-8 in a Kenyan cohort. Clin Transl Med 7:26
McGrath, Christine J; Singa, Benson; Langat, Agnes et al. (2018) Non-disclosure to male partners and incomplete PMTCT regimens associated with higher risk of mother-to-child HIV transmission: a national survey in Kenya. AIDS Care 30:765-773
Njuguna, Irene N; Wagner, Anjuli D; Omondi, Vincent O et al. (2018) Financial Incentives for Pediatric HIV Testing in Kenya. Pediatr Infect Dis J 37:1142-1144
Stone, Mars; Bainbridge, John; Sanchez, Ana M et al. (2018) Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV Isolates. J Clin Microbiol 56:
Ronen, Keshet; Unger, Jennifer A; Drake, Alison L et al. (2018) SMS messaging to improve ART adherence: perspectives of pregnant HIV-infected women in Kenya on HIV-related message content. AIDS Care 30:500-505
Roberts, Sarah T; Flaherty, Brian P; Deya, Ruth et al. (2018) Patterns of Gender-Based Violence and Associations with Mental Health and HIV Risk Behavior Among Female Sex Workers in Mombasa, Kenya: A Latent Class Analysis. AIDS Behav 22:3273-3286
Duarte, Horacio A; Beck, Ingrid A; Levine, Molly et al. (2018) Implementation of a point mutation assay for HIV drug resistance testing in Kenya. AIDS 32:2301-2308
Herbeck, Joshua T; Peebles, Kathryn; Edlefsen, Paul T et al. (2018) HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine. Vaccine 36:514-520
Shapiro, Adrienne E; van Heerden, Alastair; Schaafsma, Torin T et al. (2018) Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in South Africa and Uganda. J Int AIDS Soc 21:

Showing the most recent 10 out of 1275 publications